Lake Street analyst Brooks O’Neil downgraded Surmodics to Hold from Buy with a price target of $43, down from $75, after the company agreed to be acquired by GTCR for $43.00 per share in cash. The firm does not believe there will be another bid and expects the transaction to close, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRDX: